[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201504264WA - Modulated lysine variant species compositions and methods for producing and using the same - Google Patents

Modulated lysine variant species compositions and methods for producing and using the same

Info

Publication number
SG11201504264WA
SG11201504264WA SG11201504264WA SG11201504264WA SG11201504264WA SG 11201504264W A SG11201504264W A SG 11201504264WA SG 11201504264W A SG11201504264W A SG 11201504264WA SG 11201504264W A SG11201504264W A SG 11201504264WA SG 11201504264W A SG11201504264W A SG 11201504264WA
Authority
SG
Singapore
Prior art keywords
producing
methods
same
variant species
lysine variant
Prior art date
Application number
SG11201504264WA
Inventor
Kartik Subramanian
Thiele Mayda Perez
Xiaobei Zeng
Chee Furng Wong
Zehra Kaymakcalan
Ying Jing
Christopher Chumsae
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201504264W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11201504264WA publication Critical patent/SG11201504264WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
SG11201504264WA 2012-04-20 2013-10-18 Modulated lysine variant species compositions and methods for producing and using the same SG11201504264WA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261636469P 2012-04-20 2012-04-20
US201261696207P 2012-09-02 2012-09-02
PCT/US2013/031389 WO2013158273A1 (en) 2012-04-20 2013-03-14 Methods to modulate c-terminal lysine variant distribution
PCT/US2013/065720 WO2014143184A1 (en) 2012-04-20 2013-10-18 Modulated lysine variant species compositions and methods for producing and using the same

Publications (1)

Publication Number Publication Date
SG11201504264WA true SG11201504264WA (en) 2015-09-29

Family

ID=48040434

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504264WA SG11201504264WA (en) 2012-04-20 2013-10-18 Modulated lysine variant species compositions and methods for producing and using the same

Country Status (9)

Country Link
US (3) US9181572B2 (en)
EP (1) EP2836513A1 (en)
KR (1) KR20150131303A (en)
AU (1) AU2013381759B2 (en)
BR (1) BR112015019879A2 (en)
CA (1) CA2895402A1 (en)
HK (1) HK1206756A1 (en)
SG (1) SG11201504264WA (en)
WO (2) WO2013158273A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
MX366910B (en) * 2013-03-15 2019-07-30 Janssen Biotech Inc Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins.
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
KR102118240B1 (en) * 2013-08-20 2020-06-03 레크 파마슈티칼스 디.디. CELL CULTURE MEDIUM AND PROCESS FOR CONTROLLING α-AMIDATION AND/OR C-TERMINAL AMINO ACID CLEAVAGE OF POLYPEPTIDES
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016022377A2 (en) * 2014-08-05 2016-02-11 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
TW201628649A (en) 2014-10-09 2016-08-16 再生元醫藥公司 Process for reducing subvisible particles in a pharmaceutical formulation
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI797060B (en) 2015-08-04 2023-04-01 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
WO2017053482A1 (en) 2015-09-22 2017-03-30 Genentech, Inc. Expression of fc-containing proteins
WO2017122157A1 (en) * 2016-01-14 2017-07-20 Dr. Reddy’S Laboratories Limited Cell culture process
CA3013336A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
WO2018027195A1 (en) * 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
AU2017312785B2 (en) 2016-08-16 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
EP3500586B1 (en) * 2016-10-17 2021-02-24 Enzene Biosciences Ltd. Continuous process for reducing heterogeneity of therapeutic protein
US10613063B2 (en) 2016-10-25 2020-04-07 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
KR102701102B1 (en) * 2017-02-17 2024-08-29 론자 리미티드 Method for producing a biological product variant
US10702596B2 (en) 2017-07-05 2020-07-07 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
US10435433B2 (en) 2017-07-05 2019-10-08 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
US12042538B2 (en) 2017-09-19 2024-07-23 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
US11884698B2 (en) 2018-07-02 2024-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for preparing a polypeptide from a mixture

Family Cites Families (588)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887430A (en) 1972-02-24 1975-06-03 Dow Chemical Co Culture medium for tissue culture techniques
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
ATE115411T1 (en) 1981-09-08 1994-12-15 Univ Rockefeller ANTIBODIES AGAINST A COMPOSITION WITH MEDIATOR ACTIVITY AND ITS USE IN A PHARMACEUTICAL COMPOSITION.
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4704366A (en) 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
DE3431140A1 (en) 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg ENHANCER FOR EUKARYOTIC EXPRESSION SYSTEMS
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
ATE114673T1 (en) 1985-08-16 1994-12-15 Univ Rockefeller ANABOLIC ACTIVITY MODULATOR AND ITS USES.
IT206190Z2 (en) 1985-12-17 1987-07-13 Iveco Fiat IMPROVING THE BODYWORK OF A HEAVY VEHICLE
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4925796A (en) 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3631229A1 (en) 1986-09-13 1988-03-24 Basf Ag MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US6238891B1 (en) 1987-11-18 2001-05-29 Cetus Oncology Corporation Method of increasing product expression through solute stress
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
WO1990000902A1 (en) 1988-07-18 1990-02-08 Chiron Corporation Monoclonal antibodies reactive with cachectin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
ATE135397T1 (en) 1988-09-23 1996-03-15 Cetus Oncology Corp CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS
US5126250A (en) 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE68914244T2 (en) 1988-10-24 1994-10-27 Otsuka Pharma Co Ltd Monoclonal antibody.
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
ES2096553T3 (en) 1988-12-19 1997-03-16 American Cyanamid Co METHOD FOR THE TREATMENT OF ENDOTOXIC SHOCK IN A MAMMAL ANIMAL.
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE4009603A1 (en) 1989-03-30 1990-10-04 Leybold Ag Lock chamber for substrate
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US4933435A (en) 1989-04-05 1990-06-12 Bioprobe International Antibody purification process
US5169936A (en) 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
DE10399036I1 (en) 1989-08-07 2004-04-01 Peptide Technology Ltd Binding ligand for tumor necrosis factor.
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
AU646695B2 (en) 1990-04-09 1994-03-03 Immunex Corporation Isolated viral protein cytokine antagonists
DE4037604A1 (en) 1990-04-25 1991-10-31 Bayer Ag Use of anti-TNF antibodies to treat ischaemia and its sequelae - esp. to increase survival rate after myocardial infarct and transplants
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5378612A (en) 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (en) 1990-08-29 2005-08-15 Genpharm Int TRANSGENIC MICE CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB2279077B (en) 1990-12-21 1995-06-14 Celltech Ltd Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
DE07006112T1 (en) 1991-03-18 2010-01-21 New York University Monoclonal and chimeric antibodies to human tumor necrosis factor
US20070298040A1 (en) 1991-03-18 2007-12-27 Centocor, Inc. Methods of treating seronegative arthropathy with anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE69233367T2 (en) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla LIBRARIES OF HETERODIMERIC RECEPTORS BY PHAGEMIDES
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
US5328985A (en) 1991-07-12 1994-07-12 The Regents Of The University Of California Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
JP3502093B2 (en) 1991-07-15 2004-03-02 ザ・ウエルカム・ファウンデーション・リミテッド Production of antibodies
DE69229477T2 (en) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methods for the production of humanized antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993011793A1 (en) 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
WO1993019751A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0585705B1 (en) 1992-08-28 1998-11-04 Bayer Corporation Use of monoclonal antibodies to TNF to treat bacterial meningitis
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
DE69312077T2 (en) 1992-10-08 1997-10-30 Kennedy Inst Of Rheumatology TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES
WO1994008609A1 (en) 1992-10-15 1994-04-28 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-α FUNCTION
AU682670B2 (en) 1993-02-05 1997-10-16 Becton Dickinson & Company Syringe needle isolation device
JPH06292592A (en) 1993-02-09 1994-10-21 Snow Brand Milk Prod Co Ltd Production of glycoprotein
PT614984E (en) 1993-03-05 2001-12-28 Bayer Ag ANTI-TNF HUMAN ANTIBODIES
DE4307508A1 (en) 1993-03-10 1994-09-15 Knoll Ag Use of anti-TNF antibodies as a medicine in the treatment of heart failure (heart muscle weakness)
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH08510642A (en) 1993-05-12 1996-11-12 ゾマ コーポレイション Immunotoxin consisting of gelonin and antibody
ATE157100T1 (en) 1993-06-03 1997-09-15 Therapeutic Antibodies Inc ANTICODEPERFRAGMENTS IN THERAPY
EP0724651B1 (en) 1993-10-19 2008-08-20 The Scripps Research Institute Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
WO1995023813A1 (en) 1994-03-04 1995-09-08 Merck & Co., Inc. In vitro antibody affinity maturation using alanine scanning mutagenesis
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
JPH07289288A (en) 1994-04-27 1995-11-07 L T T Kenkyusho:Kk Method for evaluating effect of antirheumatic medicine
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
JPH10503179A (en) 1994-06-24 1998-03-24 イミュネックス・コーポレーション Controlled release polypeptide composition and method of treating inflammatory bowel disease
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US5561053A (en) 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US5616487A (en) 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
SE503424C2 (en) 1994-11-14 1996-06-10 Pharmacia Ab Process for purification of recombinant coagulation factor VIII
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5607400A (en) 1995-05-19 1997-03-04 Becton, Dickinson And Company Pre-fillable syringe and stopper assembly therefor
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ES2434840T3 (en) 1995-07-27 2013-12-17 Genentech, Inc. Formulation of stable isotonic lyophilized protein
JP4306813B2 (en) 1995-09-19 2009-08-05 アスビオファーマ株式会社 New method for culturing animal cells
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AR005035A1 (en) 1995-12-11 1999-04-07 Merck Patent Ges Mit Beschränkter Haftung PROCEDURE TO PREPARE RECOMBINANT PROTEINS IN E. COLI, BY FERMENTATION WITH GREAT CONCENTRATION OF CELLS.
JPH09173450A (en) 1995-12-26 1997-07-08 Nissho Corp Prefilled syringe
RO123028B1 (en) 1996-02-09 2010-07-30 Abbott Laboratories (Bermuda) Ltd. Human antibodies that bind human tnf alpha
ES2180689T3 (en) 1996-04-19 2003-02-16 Nestle Sa IMMORTALIZED LINE OF HUMAN COLON EPITHELIAL CELLS.
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
EP0953041A4 (en) 1996-08-30 2003-01-29 Life Technologies Inc Serum-free mammalian cell culture medium, and uses thereof
US20040171152A1 (en) 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
ATE449111T1 (en) 1996-11-27 2009-12-15 Genentech Inc AFFINITY PURIFICATION OF POLYPEPTIDE PROTEINS ON A PROTEIN A MATRIX
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
GB9625175D0 (en) 1996-12-04 1997-01-22 Medi Cult As Serum-free cell culture media
JP3293122B2 (en) 1996-12-13 2002-06-17 ニプロ株式会社 Prefilled syringe
FR2759585B1 (en) 1997-02-17 1999-06-11 Sanofi Sa PHARMACEUTICAL FORMULATIONS PRESENTED IN A DRY FORM FOR THE ORAL ADMINISTRATION OF A CYCLIC QUATERNARY AMMONIUM COMPOUND
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
CO4940438A1 (en) 1997-04-28 2000-07-24 Lilly Co Eli IMPROVED METHODS FOR THE PROCESSING OF ACTIVATED C PROTEIN
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2292730C (en) 1997-06-13 2008-09-16 Genentech, Inc. Stabilized antibody formulation
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP2002506353A (en) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド Methods and compositions for galactosylated glycoproteins
US20040191256A1 (en) 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
SE9703425D0 (en) 1997-09-23 1997-09-23 Pharmacia & Upjohn Ab Prefilled ampoules and manufacture thereof
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
ATE419009T1 (en) 1997-10-31 2009-01-15 Genentech Inc METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS
US20040136986A1 (en) 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DE19751219A1 (en) 1997-11-19 1999-05-27 Vetter & Co Apotheker Syringe, especially prefilled syringe, or carpule
DK1036179T4 (en) 1997-12-03 2014-03-31 Roche Diagnostics Gmbh Process for the preparation of polypeptides with suitable glycosylation
AU1663599A (en) 1997-12-19 1999-07-12 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
EP2253548A1 (en) 1998-03-13 2010-11-24 Becton, Dickinson and Company Method for manufacturing, filling and packaging medical containers
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO1999057246A1 (en) 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
DE69930424T2 (en) 1998-05-06 2006-12-14 Genentech, Inc., South San Francisco Anti-HER2 antibody composition
DK1308455T3 (en) 1998-05-06 2006-07-31 Genentech Inc Composition comprising anti-HER2 antibodies
DE19821933C1 (en) 1998-05-15 1999-11-11 Disetronic Licensing Ag Device for administering an injectable product
DE19822031C2 (en) 1998-05-15 2000-03-23 Disetronic Licensing Ag Auto injection device
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
PT1914244E (en) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Method of modulating the activity of functional immune molecules
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
JP4543131B2 (en) 1999-04-26 2010-09-15 ジェネンテック， インコーポレイテッド Cell culture methods for glycoproteins
CA2371427A1 (en) 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
AT409379B (en) 1999-06-02 2002-07-25 Baxter Ag MEDIUM FOR PROTEIN- AND SERUM-FREE CELL CULTURE
EP1200179B8 (en) 1999-07-30 2007-02-21 Genentech, Inc. Charged filtration membranes and uses therefor
WO2001023592A2 (en) 1999-09-27 2001-04-05 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
JP2001120262A (en) 1999-10-26 2001-05-08 Welfide Corp Method for enhancing production of physiologically active substance
AR026743A1 (en) 1999-12-09 2003-02-26 Pharmacia Ab PRODUCTION OF PEPTIDES
KR20010056451A (en) 1999-12-15 2001-07-04 윤재승 Arginine-enriched medium used for mass-producing recombinant protein in animal cell culture
AU2228901A (en) 1999-12-28 2001-07-09 Chugai Seiyaku Kabushiki Kaisha Stable antibody compositions and injection preparations
AU783973B2 (en) 2000-02-08 2006-01-12 Genentech Inc. Improved galactosylation of recombinant glycoproteins
WO2001058956A2 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
GB0003231D0 (en) 2000-02-11 2000-04-05 Medi Cult As Cell culture media
JP2001218840A (en) 2000-02-14 2001-08-14 Kanegafuchi Chem Ind Co Ltd Adsorbent for transforming growth factor. beta, adsorbing/removing method, and adsorber
JP3591636B2 (en) 2000-04-03 2004-11-24 ニプロ株式会社 Prefilled syringe
AU2001246846A1 (en) 2000-04-06 2001-10-23 Chugai Seiyaku Kabushiki Kaisha Immunoassay of anti-hm1.24 antibody
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
CA2412701A1 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
WO2002002793A1 (en) 2000-07-05 2002-01-10 Japan As Represented By Secretary Of Osaka University Process for producing glycoprotein
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US20060018907A1 (en) 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US6635448B2 (en) 2000-08-21 2003-10-21 Clonexdevelopment, Inc. Methods and compositions for increasing protein yield from a cell culture
DE60141908D1 (en) 2000-10-02 2010-06-02 Novo Nordisk Healthcare Ag GLYCO FORMS OF FACTOR VII
US20090151023A1 (en) 2000-11-13 2009-06-11 Viktor Kuvshinov Transformation system for Camelina sativa
DE60230858D1 (en) 2001-02-15 2009-03-05 Centocor Inc CHEMICALLY DEFINED MEDIUM FOR CULTIVATED MAMMALIAN CELLS
AU2002256005A1 (en) 2001-03-27 2002-10-08 Smithkline Beecham Corporation Control of glycoforms in igg
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
KR100770065B1 (en) 2001-05-11 2007-10-24 기린 파마 가부시끼가이샤 Artificial Human Chromosome Containing Human Antibody ? Light Chain Gene
AU2002311976A1 (en) 2001-05-24 2002-12-03 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
WO2002096461A1 (en) 2001-05-25 2002-12-05 Abbott Gmbh & Co. Kg Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
DE60235989D1 (en) 2001-06-26 2010-05-27 Amgen Fremont Inc ANTIBODIES AGAINST OPGL
CA2455365C (en) 2001-08-03 2014-07-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
GB0119520D0 (en) 2001-08-10 2001-10-03 Owen Mumford Ltd Improvements relating to injection devices
EP1434857B1 (en) 2001-10-02 2007-08-01 Novo Nordisk Health Care AG Method for production of recombinant proteins in eukaryote cells
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
DE60231055D1 (en) 2001-11-12 2009-03-19 Novo Nordisk As CLEANING OF PEPTIDES USING METAL-ION-AFFINITY CHROMATOGRAPHY
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
AU2002356749A1 (en) 2001-11-28 2003-06-10 Hermann Katinger Process for the production of polypeptides in mammalian cell cultures
NZ533133A (en) 2001-11-28 2006-02-24 Sandoz Ag Method for producing a recombinant polypeptide
HUP0402226A2 (en) 2001-11-28 2005-02-28 Sandoz Ag. Cell culture process
AU2002359816B2 (en) 2001-12-21 2006-07-13 Immunex Corporation Methods for purifying protein
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
US20030161828A1 (en) 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
JP4141156B2 (en) 2002-03-15 2008-08-27 日本ベクトン・ディッキンソン株式会社 Prefilled syringe with plunger retraction limit mechanism
MXPA04009381A (en) 2002-03-27 2005-01-25 Immunex Corp Methods for increasing polypeptide production.
US20030190710A1 (en) 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
KR20100112206A (en) 2002-04-11 2010-10-18 메디뮨 엘엘씨 Preservation of bioactive materials by spray drying
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
CA2482448C (en) 2002-04-11 2014-07-08 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
JP4319979B2 (en) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド Non-affinity purification of proteins
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040029229A1 (en) 2002-05-20 2004-02-12 Reeves Philip J. High level protein expression system
ATE552873T1 (en) 2002-07-02 2012-04-15 Terumo Corp SYRINGE AND PREFILLED SYRINGE
JP4510938B2 (en) 2002-07-15 2010-07-28 イミュネックス・コーポレーション Method and medium for regulating sialic acid addition of proteins produced by mammalian cells
JP2006506465A (en) 2002-07-19 2006-02-23 アボツト・バイオテクノロジー・リミテツド Treatment of TNFα related diseases
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
WO2004026891A2 (en) 2002-09-18 2004-04-01 Genencor International, Inc. Protein purification
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004042012A2 (en) 2002-11-01 2004-05-21 Bayer Healthcare Llc Process for concentration of macromolecules
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DE10254321A1 (en) 2002-11-21 2004-06-17 Arzneimittel Gmbh Apotheker Vetter & Co. Ravensburg Pre-filled syringe
US20040101939A1 (en) 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
US20040162414A1 (en) 2002-11-22 2004-08-19 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US7378110B2 (en) 2002-12-17 2008-05-27 Med Immune Vaccines, Inc. High pressure spray-dry of bioactive materials
KR20050088136A (en) 2002-12-23 2005-09-01 브리스톨-마이어스 스큅 컴퍼니 Mammalian cell culture processes for protein production
PL377603A1 (en) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
JP2004229750A (en) 2003-01-28 2004-08-19 Nipro Corp Prefilled syringe and production method for barrel thereof
WO2004076485A1 (en) 2003-02-28 2004-09-10 Lonza Biologics Plc. Antibody purification by protein a and ion exchange chromatography
AU2004235017B2 (en) 2003-05-01 2009-06-04 Dsm Ip Assets B.V. Process for the production of biological substances by perfusion culturing of suspended animal cells
AR044302A1 (en) 2003-05-13 2005-09-07 Ares Trading Sa FORMULATIONS WITH LIQUID PROTEINS STABILIZED IN PHARMACEUTICAL CONTAINERS
ES2344789T5 (en) 2003-05-15 2017-06-14 Wyeth Llc Restricted glucose feeding for animal cell culture
GB2404665B (en) 2003-08-08 2005-07-06 Cambridge Antibody Tech Cell culture
US20050075611A1 (en) 2003-10-01 2005-04-07 Hetzler Kevin G. Low extractable, thermoplastic syringe and tip cap
EP1673452B1 (en) 2003-10-10 2015-12-23 Novo Nordisk Health Care AG Method for large-scale production of a polypeptide in eukaryote cells
FR2861080B1 (en) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement ANTIBODIES HAVING AN OPTIMIZED FUCOSE AND GALACTOSE RATE
DE602004026343D1 (en) 2003-10-24 2010-05-12 Amgen Inc PROCESS FOR PURIFYING PROTEINS IN A FLOW FRACTION FROM CHROMATOGRAPHY WITH HYDROPHOBIC INTERACTIONS
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
DE10355251A1 (en) 2003-11-26 2005-06-23 Merck Patent Gmbh Water-based pharmaceutical preparation for treatment of tumors has active ingredient effective against receptor of endothelial growth factor receptor
CA2894300A1 (en) 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
PL1703893T3 (en) 2003-12-23 2012-09-28 Genentech Inc Novel anti-il 13 antibodies and uses thereof
CA2548940A1 (en) 2003-12-23 2005-07-14 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
US20080058507A1 (en) 2004-02-11 2008-03-06 Hui Liu Method For The Removal Of Aggregate Proteins From Recombinant Samples Using Ion Exchange Chromatography
BRPI0507608A (en) 2004-02-12 2007-07-03 Merck Patent Gmbh highly concentrated liquid anti-egfr antibody formulations
EP1718386A1 (en) 2004-02-27 2006-11-08 GE Healthcare Bio-Sciences AB A process for the purification of antibodies
CN1234725C (en) 2004-04-07 2006-01-04 陈志南 High performance quick purifying method for preparing piecewise antibody
TWI556829B (en) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 Multiple-variable dose regimen for treating tnfα-related disorders
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
CN104611245A (en) 2004-04-15 2015-05-13 格利科菲公司 Production of galactosylated glycoproteins in lower eukaryotes
RU2006138181A (en) 2004-05-04 2008-06-10 Ново Нордиск Хелс Кеа Аг (Ch) O-RELATED Glycoforms of Polypeptides and a Method for Their Production
EP1771477A2 (en) 2004-07-21 2007-04-11 Glycofi, Inc. Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
TWI384069B (en) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals Production of polypeptides
AU2005292358B2 (en) 2004-09-30 2011-06-16 Bayer Healthcare Llc Devices and methods for integrated continuous manufacturing of biological molecules
US20060083741A1 (en) 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
WO2007011390A2 (en) 2004-10-09 2007-01-25 Government Of The United States As Represented By The Secretary Of The Army Large-scale production of human serum butyrylcholinesterase as a bioscavenger
US7714112B2 (en) 2004-10-21 2010-05-11 Ge Healthcare Bio-Sciences Ab Method of antibody purification
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP2008529495A (en) 2005-02-04 2008-08-07 グラクソ グループ リミテッド Optimization of heterologous polypeptide expression
WO2006085209A1 (en) 2005-02-11 2006-08-17 Agency For Science, Technology And Research Methods of proliferating stem cells
WO2006084826A1 (en) 2005-02-11 2006-08-17 Novo Nordisk Health Care Ag Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
ES2797480T3 (en) 2005-03-11 2020-12-02 Wyeth Llc A weak partition chromatography procedure
US20060252672A1 (en) 2005-04-05 2006-11-09 Betenbaugh Michael J Protein N-glycosylation of eukaryotic cells using dolichol-linked oligosaccharide synthesis pathway, other N-gylosylation-increasing methods, and engineered hosts expressing products with increased N-glycosylation
JP2008535913A (en) 2005-04-11 2008-09-04 メダレックス インコーポレーティッド Protein purification method
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006113743A2 (en) 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
US8349991B2 (en) 2005-04-19 2013-01-08 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
CA2898009C (en) 2005-05-16 2018-03-27 Rebecca S. Hoffman Use of tnfa inhibitor for treatment of erosive polyarthritis
WO2006133148A2 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
CA2610315A1 (en) 2005-06-03 2006-12-07 Biovitrum Ab (Publ) Process for cultivating animal cells comprising the feeding of plant-derived peptones
PT1896071E (en) 2005-06-30 2015-07-09 Janssen Biotech Inc Methods and compositions with enhanced therapeutic activity
SG10201508995QA (en) 2005-07-26 2015-11-27 Sangamo Biosciences Inc Targeted integration and expression of exogenous nucleic acid sequences
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006283560B2 (en) 2005-08-19 2011-12-08 Centocor, Inc. Proteolysis resistant antibody preparations
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
MX2008002596A (en) 2005-08-26 2008-03-14 Ares Trading Sa Process for the preparation of glycosylated interferon beta.
WO2007028144A2 (en) 2005-09-02 2007-03-08 Glycofi, Inc Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
PE20070796A1 (en) 2005-10-24 2007-08-15 Wyeth Corp PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS
NZ595340A (en) 2005-11-01 2013-04-26 Abbott Biotech Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2455100A3 (en) 2005-11-07 2012-11-07 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US7972810B2 (en) 2005-12-08 2011-07-05 Amgen Inc. Production of glycoproteins using manganese
US7988675B2 (en) 2005-12-08 2011-08-02 West Pharmaceutical Services Of Delaware, Inc. Automatic injection and retraction devices for use with pre-filled syringe cartridges
ES2474573T3 (en) 2006-01-04 2014-07-09 Baxter International Inc Cell culture medium without oligopeptides
JP4682850B2 (en) 2006-01-12 2011-05-11 ニプロ株式会社 Prefilled syringe
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
JP6084761B2 (en) 2006-04-05 2017-02-22 ザ ロックフェラー ユニバーシティー Polypeptides with enhanced anti-inflammatory properties and reduced cytotoxic properties and related methods
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20090317399A1 (en) 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
EP2012586A4 (en) 2006-04-10 2010-08-18 Abbott Biotech Ltd Uses and compositions for treatment of ankylosing spondylitis
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
CN103255162A (en) 2006-05-19 2013-08-21 格利科菲公司 Erythropoietin compositions
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
WO2009017491A1 (en) 2006-06-14 2009-02-05 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
EP2043711A4 (en) 2006-06-30 2017-08-30 AbbVie Biotechnology Ltd Automatic injection device
EP3255141B1 (en) 2006-07-13 2021-12-01 Wyeth LLC Production of antibodies with improved glycosylation pattern
WO2008028974A1 (en) 2006-09-08 2008-03-13 Novo Nordisk A/S Methods of optimizing chromatographic separation of polypeptides
ES2533964T5 (en) 2006-09-10 2024-05-09 Glycotope Gmbh Use of human cells of myeloid leukemic origin for antibody expression
EP2527425A1 (en) 2006-09-13 2012-11-28 Abbott Laboratories Cell culture improvements
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008036600A2 (en) 2006-09-18 2008-03-27 Genentech, Inc. Methods of protein production
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
EP2091969A4 (en) 2006-10-27 2010-05-12 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CN104072612A (en) 2006-10-27 2014-10-01 艾伯维生物技术有限公司 Crystalline anti-hTNFalpha antibodies
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
JP5065391B2 (en) 2006-12-06 2012-10-31 日本ケミカルリサーチ株式会社 Method for producing human erythropoietin
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2672979A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Selection method
JP2010514448A (en) 2006-12-28 2010-05-06 セントコア・オーソ・バイオテツク・インコーポレーテツド Methods and vectors for generating asialylated immunoglobulins
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
JP2010516651A (en) 2007-01-17 2010-05-20 メルク セローノ ソシエテ アノニム Methods for purification of Fc-containing proteins
HUE026403T2 (en) 2007-03-02 2016-06-28 Wyeth Llc Use of copper and glutamate in cell culture for production of polypeptides
JP5634710B2 (en) 2007-03-19 2014-12-03 国立大学法人 岡山大学 Medium for protein production and virus propagation
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
KR20170091174A (en) 2007-04-03 2017-08-08 옥시레인 유케이 리미티드 Glycosylation of molecules
US20120264927A1 (en) 2007-04-16 2012-10-18 Ian Christopher Parsons Methods for labeling glycans
WO2008128228A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Methods related to cell surface glycosylation
WO2008128230A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Reference glycoprotein products and related methods
EP2135093B1 (en) 2007-04-16 2015-04-15 Momenta Pharmaceuticals, Inc. Analysis of phosphorylated glycans, glcopeptides or glycoproteins by imac
CA2682735C (en) 2007-04-16 2015-06-23 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating n-glycans
WO2008128219A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Comparative analysis of protein conformations by using 2d noesy nmr spectra
WO2008128220A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Proteolytic release of glycans
US8043863B2 (en) 2007-04-16 2011-10-25 Momenta Pharmaceuticals, Inc. MS methods to evaluate glycans
AU2008240071A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Characterization of N-glycan mixtures by nuclear magnetic resonance
PT2137655E (en) 2007-04-16 2012-09-14 Momenta Pharmaceuticals Inc Defined glycoprotein products and related methods
CA2682695A1 (en) 2007-04-16 2008-10-30 Momenta Pharmaceuticals, Inc. Characterization of n-glycans using exoglycosidases
US20110213137A1 (en) 2007-04-16 2011-09-01 Momenta Pharmaceuticals, Inc. Isotopically-labeled glycans
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2008135498A2 (en) 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
EP2152856B1 (en) 2007-05-11 2012-08-29 Amgen Inc. Improved feed media
WO2008150491A2 (en) 2007-05-31 2008-12-11 Abbott Laboratories BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
WO2008150490A2 (en) 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
HUE046992T2 (en) 2007-07-09 2020-04-28 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2173380A4 (en) 2007-07-13 2011-08-31 Abbott Biotech Ltd METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR
KR100897159B1 (en) 2007-07-26 2009-05-14 보령제약 주식회사 A plant recombinant human CTLA4Ig and a method for producing the same
US8753839B2 (en) 2007-08-08 2014-06-17 Abbvie Inc. Compositions and methods for crystallizing antibodies
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CA2696210A1 (en) 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
EP2031064A1 (en) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres
JP2010536355A (en) 2007-08-31 2010-12-02 エフ．ホフマン−ラ ロシュ アーゲー Glycosylation profile analysis
US8273723B2 (en) 2007-10-12 2012-09-25 Sigma-Aldrich Co. Llc Compositions and methods for improved glycoprotein sialylation
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
ATE540315T1 (en) 2007-10-29 2012-01-15 Univ Georgia IN VIVO ISOTOPE LABELING METHODS FOR QUANTITATIVE GLYCOMICS
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
TW200938221A (en) 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PL2574676T3 (en) 2007-12-27 2017-12-29 Baxalta GmbH Cell culture processes
WO2009083246A1 (en) 2007-12-31 2009-07-09 Bayer Schering Pharma Aktiengesellschaft Antibodies to tnf alpha
US20090271164A1 (en) 2008-01-03 2009-10-29 Peng Joanna Z Predicting long-term efficacy of a compound in the treatment of psoriasis
CA2711307C (en) 2008-01-03 2020-10-27 Cornell Research Foundation, Inc. Glycosylated protein expression in prokaryotes
ES2579231T3 (en) 2008-01-15 2016-08-08 Abbvie Inc Enhanced mammalian expression vectors and uses thereof
NZ586828A (en) 2008-01-15 2012-12-21 Abbott Gmbh & Co Kg Powdered antibody compositions and methods of making same
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
WO2009099545A1 (en) 2008-01-30 2009-08-13 Abbott Laboratories Compositions and methods for crystallizing antibody fragments
CA2717129A1 (en) 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2009114641A1 (en) 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
EP2271671A2 (en) 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
CA2719923A1 (en) 2008-04-08 2009-10-15 Amyris Biotechnologies, Inc. Expression of heterologous sequences
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009135656A1 (en) 2008-05-06 2009-11-12 Lonza Biologics Plc. A method for the purification of antibodies using displacement chromatography
WO2009149189A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US8318416B2 (en) 2008-08-08 2012-11-27 Biogen Idec Ma Inc. Nutrient monitoring and feedback control for increased bioproduct production
KR102196883B1 (en) 2008-08-14 2020-12-30 제넨테크, 인크. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
US8080415B2 (en) 2008-09-26 2011-12-20 Eureka Therapeutics, Inc. Modified host cells and uses thereof
WO2010043703A1 (en) 2008-10-17 2010-04-22 Dsm Ip Assets B.V. Removal of host cell proteins
WO2010048192A2 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
KR20110091678A (en) 2008-10-20 2011-08-12 아보트 러보러터리즈 Isolation and purification of antibodies using protein a affinity chromatography
WO2010048183A1 (en) 2008-10-20 2010-04-29 Abbott Laboratories Antibodies that bind to il-18 and methods of purifying the same
GB0821100D0 (en) 2008-11-18 2008-12-24 Hansa Medical Ab Antibodies
US8729241B2 (en) 2008-12-19 2014-05-20 Momenta Pharmaceuticals, Inc. Characterization of O-linked glycans
CA2743181A1 (en) 2008-12-19 2010-06-24 Momenta Pharmaceuticals, Inc. Methods related to modified glycans
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
WO2010080062A1 (en) 2009-01-08 2010-07-15 Ge Healthcare Bio-Sciences Ab Separation method using single polymer phase systems
BRPI0924078A2 (en) 2009-01-22 2018-10-16 Momenta Pharmaceuticals Inc n-glycans containing galactose-alpha-1,3-galactose in cho cell derived glycoprotein products.
US20100292443A1 (en) 2009-02-26 2010-11-18 Sabbadini Roger A Humanized platelet activating factor antibody design using anti-lipid antibody templates
WO2010102114A1 (en) 2009-03-05 2010-09-10 Biogen Idec Ma Inc. Purification of immunoglobulins
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
CA2756889C (en) 2009-04-01 2017-09-05 Evec Incorporated Monoclonal antibody capable of binding to specific discontinuous epitope occurring in ad1 region of human cytomegalovirus gb glycoprotein, and antigen-binding fragment thereof
KR20110139292A (en) 2009-04-20 2011-12-28 화이자 인코포레이티드 Control of protein glycosylation and compositions and methods relating thereto
US20120282654A1 (en) 2009-04-29 2012-11-08 Schering Corporation Antibody purification
MX2011011541A (en) 2009-04-29 2012-02-28 Abbott Biotech Ltd Automatic injection device.
EP2427211A4 (en) 2009-05-04 2013-05-01 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US20120329709A1 (en) 2009-05-26 2012-12-27 Brian Edward Collins Production of glycoproteins
WO2010136515A1 (en) 2009-05-28 2010-12-02 Boehringer Ingelheim International Gmbh Method for a rational cell culturing process
WO2010136209A1 (en) 2009-05-28 2010-12-02 ETH Zürich N-glycan core beta-galactosyltransferase and uses thereof
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
CN102482633A (en) 2009-07-06 2012-05-30 弗·哈夫曼-拉罗切有限公司 Method of culturing eukaryotic cells
JP5540095B2 (en) 2009-07-24 2014-07-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Optimization of antibody production
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
RU2017138926A (en) 2009-08-11 2019-02-11 Дженентек, Инк. PRODUCTION OF PROTEINS IN CULTURAL MEDIA WITHOUT GLUTAMINE
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
WO2011024025A1 (en) 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
EP2325296A1 (en) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20110136682A1 (en) 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
EP2513135B1 (en) 2009-12-18 2020-04-22 CSL Limited Method of purifying polypeptides
WO2011090719A2 (en) 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd. Protein purification by ion exchange
WO2011097301A2 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
JP2013519652A (en) 2010-02-12 2013-05-30 ディーエスエム アイピー アセッツ ビー．ブイ． Single unit antibody purification
EP2545066B1 (en) 2010-03-10 2017-09-20 F. Hoffmann-La Roche AG Method for purifying immunoglobulin solutions
EP2544538B1 (en) 2010-03-12 2022-06-15 PureCircle USA Inc. High-purity steviol glycosides
MX2012011648A (en) 2010-04-07 2012-11-29 Momenta Pharmaceuticals Inc High mannose glycans.
TWI586806B (en) 2010-04-23 2017-06-11 建南德克公司 Production of heteromultimeric proteins
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
EP3330370B1 (en) 2010-04-26 2021-02-24 Novartis AG Process for cultivation of cho cells
PL2563904T3 (en) 2010-04-26 2015-06-30 Novartis Ag Improved cell culture medium
BR112012030197A2 (en) 2010-05-28 2015-09-29 Genentech Inc decreased lactate level and increased polypeptide production by downregulating lactate dehydrogenase and pyruvate dehydrogenase kinase expression.
EP2575884B1 (en) 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
US9428546B2 (en) 2010-07-30 2016-08-30 Pfizer Inc. Tandem purification of proteins
EP2601287B1 (en) 2010-08-05 2015-01-07 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
DE102010038990A1 (en) 2010-08-06 2012-02-09 Robert Bosch Gmbh Shaft bearing device for a hand tool
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US20120123688A1 (en) 2010-09-17 2012-05-17 Abbott Laboratories Raman spectroscopy for bioprocess operations
CN103201003B (en) 2010-09-20 2016-04-13 Abbvie公司 Adopt SMBC antibody purification
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
NZ609903A (en) 2010-10-08 2015-04-24 Cadila Healthcare Ltd Expression vector for high level expression of recombinant proteins
WO2012051147A1 (en) 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
KR101898302B1 (en) 2010-10-15 2018-09-13 제이씨알 파마 가부시키가이샤 Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
EP2450375A1 (en) 2010-11-09 2012-05-09 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
SG190069A1 (en) 2010-11-11 2013-06-28 Abbvie Biotechnology Ltd IMPROVED HIGH CONCENTRATION ANTI-TNFa ANTIBODY LIQUID FORMULATIONS
US20130331554A1 (en) 2010-11-15 2013-12-12 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
US20120149878A1 (en) 2010-12-08 2012-06-14 Gillespie Ronald Protein purification
UY33827A (en) 2010-12-22 2012-07-31 Abbott Lab MEDIUM-IMMUNOGLOBULIN UNION PROTEINS AND ITS USES
NZ611862A (en) 2010-12-28 2015-05-29 Chugai Pharmaceutical Co Ltd Animal cell culturing method
CA2821926A1 (en) 2011-01-07 2012-07-12 Abbvie Inc. Anti-il-12/il-23 antibodies and uses thereof
TW201309330A (en) 2011-01-28 2013-03-01 Abbott Lab Compositions containing glycosylated antibodies and uses thereof
AR085302A1 (en) 2011-02-24 2013-09-18 Sanofi Sa METHOD OF PRODUCTION OF STIRATED ANTIBODIES
SG192632A1 (en) 2011-03-06 2013-09-30 Merck Serono Sa Low fucose cell lines and uses thereof
WO2012122544A2 (en) 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
TWI671315B (en) 2011-03-28 2019-09-11 法商賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US20140108084A1 (en) 2012-10-12 2014-04-17 Crestron Electronics, Inc. Initiating Schedule Management Via Radio Frequency Beacons
PL2702164T3 (en) 2011-04-29 2016-06-30 Biocon Res Limited A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
US20120301510A1 (en) 2011-04-29 2012-11-29 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers coupled to cd1d-restricted antigens and methods of use
US9670519B2 (en) 2011-04-29 2017-06-06 Biocon Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
WO2012158551A1 (en) 2011-05-13 2012-11-22 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
WO2013006461A1 (en) 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
CN103827292B (en) 2011-07-01 2018-01-26 安姆根有限公司 Mammaliancellculture
JP6454547B2 (en) 2011-07-06 2019-01-16 ゲンマブ エー／エス Regulation of complement-dependent cytotoxicity by modification of the C-terminus of antibody heavy chain
EP2729561A4 (en) 2011-07-08 2015-06-24 Momenta Pharmaceuticals Inc Cell culture process
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013013013A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
WO2013021279A2 (en) 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies
US20130149300A1 (en) 2011-09-27 2013-06-13 Icon Genetics Gmbh MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS
WO2013066707A1 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Chromatography process for resolving heterogeneous antibody aggregates
CN104023804B (en) 2011-11-02 2017-05-24 弗·哈夫曼-拉罗切有限公司 Overload And Elute Chromatography
BR112014014549A2 (en) 2011-12-19 2020-09-24 The Rockefeller University non-sialylated popipeptide anti-inflammatory
SG10201609982PA (en) 2012-03-07 2017-01-27 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha anitbodies
SG10201701224UA (en) 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
TW201348246A (en) 2012-05-21 2013-12-01 Abbvie Inc Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2855745A4 (en) 2012-06-01 2016-01-20 Momenta Pharmaceuticals Inc Methods related to adalimumab
JP2015519382A (en) 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical formulations for therapeutic antibodies
ES2975188T3 (en) 2012-07-26 2024-07-03 Momenta Pharmaceuticals Inc Glycoproteins with anti-inflammatory properties
KR102410763B1 (en) 2012-08-17 2022-06-20 모르포시스 아게 Complex-specific antibodies and antibody fragments and its use
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
CA3153799A1 (en) 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
US20150252108A1 (en) 2012-09-26 2015-09-10 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
EP3514175A1 (en) 2012-12-17 2019-07-24 Laboratoire Français du Fractionnement et des Biotechnologies Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
WO2014099636A1 (en) 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
AU2014217561B2 (en) 2013-02-13 2018-11-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-alpha antibodies and uses thereof
EP2964768B1 (en) 2013-03-08 2020-07-22 Neuclone Biologics Pty Ltd A cell expression system
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
EP2836515A1 (en) 2013-03-14 2015-02-18 AbbVie Inc. Low acidic species compositions and methods for producing and using the same
US20140271622A1 (en) 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US20140271633A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Mammalian cell culture performance through surfactant supplementation of feed media
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
TWI670279B (en) 2013-03-15 2019-09-01 美商艾爾德生物製藥股份有限公司 Antibody purification and purity monitoring
MX366910B (en) 2013-03-15 2019-07-30 Janssen Biotech Inc Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins.
US20160108450A1 (en) 2013-05-02 2016-04-21 Momenta Pharmaceutcals, Inc. Sialylated glycoproteins
KR101569783B1 (en) 2013-06-05 2015-11-19 한화케미칼 주식회사 A Method of Antibody Purification
AR096713A1 (en) 2013-06-25 2016-01-27 Cadila Healthcare Ltd PURIFICATION PROCESS FOR MONOCLONAL ANTIBODIES
AR096839A1 (en) 2013-07-06 2016-02-03 Cadila Healthcare Ltd IMPROVED PROCESS FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES
RU2662558C2 (en) 2013-07-19 2018-07-26 Хексаль Аг Methods and compositions which allow modulation of immune responses related to administration of biopharmaceutical drug
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
PL3036320T5 (en) 2013-08-19 2024-06-10 Biogen Ma Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
KR102118240B1 (en) 2013-08-20 2020-06-03 레크 파마슈티칼스 디.디. CELL CULTURE MEDIUM AND PROCESS FOR CONTROLLING α-AMIDATION AND/OR C-TERMINAL AMINO ACID CLEAVAGE OF POLYPEPTIDES
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN106029871A (en) 2014-01-29 2016-10-12 株式会社Lg生命科学 Method for controlling galactosylation of recombinant protein through optimization of culture medium
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
WO2016022377A2 (en) 2014-08-05 2016-02-11 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
MY180732A (en) 2014-12-22 2020-12-08 Ucb Biopharma Sprl Protein manufacture
CN105777895A (en) 2015-03-19 2016-07-20 广东东阳光药业有限公司 Application of sodium phenylbutyrate in purification of antibody acidic peak
CN105777896B (en) 2015-03-19 2019-08-16 广东东阳光药业有限公司 A kind of purification process at antibody acidity peak
CN105777904B (en) 2015-03-23 2019-12-10 广东东阳光药业有限公司 cation exchange chromatography purification method of anti-TNF alpha monoclonal antibody
EP3072957B1 (en) 2015-03-23 2019-07-10 Lonza Ltd Methods for controlling protein glycosylation

Also Published As

Publication number Publication date
US20170349655A1 (en) 2017-12-07
HK1206756A1 (en) 2016-01-15
WO2013158273A1 (en) 2013-10-24
US20130280274A1 (en) 2013-10-24
US20160046708A1 (en) 2016-02-18
KR20150131303A (en) 2015-11-24
US9708400B2 (en) 2017-07-18
BR112015019879A2 (en) 2017-08-22
CA2895402A1 (en) 2014-09-18
AU2013381759A1 (en) 2015-06-04
US9181572B2 (en) 2015-11-10
AU2013381759B2 (en) 2016-12-08
WO2014143184A8 (en) 2015-01-29
EP2836513A1 (en) 2015-02-18
WO2014143184A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
HK1206756A1 (en) Modulated lysine variant species compositions and methods for producing and using the same
IL271305B (en) Anti-ntb-a antibodies and related compositions and methods
HK1216009A1 (en) Prostacylin compositions and methods for using the same
EP2836212A4 (en) Novel compositions and methods
AP2014008100A0 (en) Compositions and methods for modulating hemoglobingene family expression
EP2850190A4 (en) Compositions and methods for modulating mecp2 expression
EP2850187A4 (en) Compositions and methods for modulating pten expression
EP2694080A4 (en) Methods and compositions for modulating peripheral immune function
IL238329A0 (en) Compositions comprising peroxyacid and methods for producing and using the same
HK1206970A1 (en) Antigenic compositions and methods
ZA201408213B (en) Anti-transglutaminase 2 antibodies
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
EP2968346A4 (en) Methods and compositions for gamma-glutamyl cycle modulation
HK1199411A1 (en) Nano-emulsion composition and method for producing the same
EP2857002A4 (en) Composition for hair growth
EP2916812A4 (en) White keratin compositions
SG2014010433A (en) Stable compositions and methods for preparing the same
GB201208476D0 (en) Compositions and methods for modulating an immune response
GB201222942D0 (en) Dynamic sequence match 2
AU2012900398A0 (en) Point 10
TWM432299U (en) M1010701_3919
TWM432248U (en) M1010701_3919
TWM432296U (en) M1010701_3919
TWM432298U (en) M1010701_3919